by Beyond Lab
Luxembourg government decided to take the challenge to push personalized medicine researches with big money. In collaboration with three U.S. institutes, U. of Luxembourg will establish several research centers to build a BIOBANK which collects huge amounts of disease samples and genetic information. This proposed system will be used to promote translational research and systems biology and in the long run will build the basics for personalized medicine. Of course, this has to be helped with modern personal genomics studies.
To Beyond Lab, this initiative is an important step toward personalized medicine. With U.S. economy going slow and U.S.federal funding being flat, other countries like Luxembourg, Japan, Singapore, and even South Korea are putting big amount of money in life science. At this point, the whole thing is still at data/information collection stage. But very soon, really useful knowledge/technology will come out and some of them will bring money back to those countries who invested in the research. Although it is difficult to predict exactly a time frame, the fast growing technologies will sure prove this is the case.
Showing posts with label personalized medicine. Show all posts
Showing posts with label personalized medicine. Show all posts
Sunday, June 8, 2008
Friday, May 23, 2008
personal genomics and cancer treatment, another model
by Beyond Lab
A recent extensive study showed that different genetic mutations (personal genomics)of a single gene could result in different drug response.
The most common lung cancer - non-small cell lung cancer - is associated with mutations of a gene called EGFR. Using AstaZeneca’s cancer drug Iressa (gefitinib), this study found that patients' drug-response, to a large degree, depends on the specific mutations. Without going into the details, this study indeed support the potential application of personal genomics in medical practice. Once enough genetic, genomic and clinical information is accumulated, doctors could select treatment that will sure be effective based on patients' genome -- so called personalized medicine.
A recent extensive study showed that different genetic mutations (personal genomics)of a single gene could result in different drug response.
The most common lung cancer - non-small cell lung cancer - is associated with mutations of a gene called EGFR. Using AstaZeneca’s cancer drug Iressa (gefitinib), this study found that patients' drug-response, to a large degree, depends on the specific mutations. Without going into the details, this study indeed support the potential application of personal genomics in medical practice. Once enough genetic, genomic and clinical information is accumulated, doctors could select treatment that will sure be effective based on patients' genome -- so called personalized medicine.
Subscribe to:
Posts (Atom)
